SEC Form 4 · accession 0001209191-18-051837
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Patterson
Officer — Chief Executive Officer · Director
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 7:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 18, 2018 | M | 12,952 | $2.19 | A | 12,952 | D | |
| Common Stock | Sep 18, 2018 | S | 12,952 | $40.00 | D | 0 | D | |
| Common StockF2 | holding | — | — | — | 171,814 | I | By Matthew R. Patterson Revocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.19 | Sep 18, 2018 | M | 12,952 | D | — | Feb 4, 2025 | Common Stock | 12,952 | 128,345 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
- F3The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares will vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.